Recipharm Appoints New Business Director for Italy
News Oct 27, 2015
Recipharm has announced the appointment of a new business director for the Italian pharmaceutical market and a new General Manager at Pessac, France.
Franco Boselli joins the Business Management team as Business Director in Italy with the main task to sell Recipharm’s full service offering to Italian pharmaceutical companies. He reports to the Vice President of Business Management, Kenth Berg, and is based in Milan.
Prior to joining Recipharm, Mr Boselli worked in marketing and sales in different pharmaceutical companies in Italy. In 2009, he joined the B2B business as Business Development Manager in Mipharm, the Italian CMO, specializing in non-sterile products. In 2011, he joined Biologici Italia Laboratories, later part of the Corvette group acquired by Recipharm last year, as Business Development Director.
In this role, he managed Corvette’s key customers and was responsible for the scouting of new business, including the out-licensing of dossiers of sterile injectables and the development of new dossiers for generic products as well as sales of contract manufacturing of lyophilized and sterile formulations. Mr Boselli holds a degree in Economics from L. Bocconi University in Milan.
Bernard Pluta joins Recipharm as General Manager for the operating company in Pessac, France and will report to the Executive Vice President of Development and Technology, Carl- Johan Spak. Mr Pluta has had a long career in the pharma industry, having held executive positions in Theramex and Teva. He currently runs his own CMO consultancy business.
Mr Pluta’s primary task is to drive the performance at the company through the sales of new projects and operational excellence. He commenced his role on October 19th, replacing Stéphane Guisado who will continue in his role as General Manager in Recipharm Fontaine. Mr Pluta holds a master degree in Engineering from the French Grande Ecole of Arts & Métiers in Paris and an executive MBA from Ashridge Business School, UK.
Commenting on the appointments, Thomas Eldered, CEO of Recipharm said: “I am delighted that Mr Boselli and Mr Pluta have joined Recipharm. Both bring great skills and experience to our organization. Mr Boselli’s knowledge and expertise will be invaluable to the continuing growth and expansion of our Italian business across the whole Recipharm network. Mr Pluta’s industry expertise and solid business competence will play a key role in the task at hand to increase performance at Recipharm Pessac whilst maintaining the highest quality standards of service.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018